The global Adeno-associated virus vector manufacturing market accounted for USD 0.942 billion in 2023 and is expected to reach at USD 8.87 billion by 2034 with a CAGR of 22.61% during the forecast period 2024-2034. Rising demand for gene therapy, advances in gene editing technologies, an increase in the prevalence of genetic disorders, technological innovations in vector manufacturing, and more investment and collaboration will all fuel market expansion.
AAV-based medicines are becoming more widely available as a result of the pharmaceutical industry's increasing investment in gene therapy research and development. The need for AAV vector manufacturing services is anticipated to rise as more gene therapy candidates go through preclinical and clinical development. For instance, FUJIFILM Diosynth Biotechnologies stated in February 2024 that it has formed a strategic cooperation with a prominent gene therapy company to facilitate the development and production of AAV-based gene therapies.
By therapeutic area, the genetic disorders segment accounted for the highest revenue-grossing segment in the global Adeno-associated virus vector manufacturing market in 2023 owing to the growing demand for gene therapy treatments for a wide range of genetic diseases, coupled with advancements in AAV vector technology enabling safe and effective gene delivery. For instance, Thermo Fisher Scientific announced in March 2024 the release of the new GibcoTM AAVMAXTM Titer Kit for AAV vector manufacturing. Additionally, the oncology segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cancer, expanding research in oncology gene therapy, and the potential of AAV vectors to deliver targeted therapies with fewer side effects.
By application, the gene therapy segment accounted for the highest revenue-grossing segment in the global Adeno-associated virus vector manufacturing market in 2023 owing to the escalating demand for innovative treatments for genetic diseases, coupled with advancements in AAV vector technology facilitating safer and more efficient gene delivery. For instance, Oxford Biomedica stated in December 2023 that it would be expanding its Oxford, UK, manufacturing plant in order to meet the growing demand for the manufacture of AAV vectors. Additionally, the cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of cell-based treatments for various diseases, advancements in AAV vector technology for cell transduction, and expanding applications of cell therapies in regenerative medicine and immunotherapy.
By method, the in vitro segment accounted for the highest revenue-grossing segment in the global Adeno-associated virus vector manufacturing market in 2023 owing to the growing demand for AAV vectors in research and development applications, including cell-based assays, gene editing, and drug discovery. For instance, uniQure N.V. reported encouraging interim data from the Phase I/II clinical trial of AMT-130, an AAV-based gene therapy intended to treat Huntington's disease, in January 2024. Additionally, the in vivo segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of AAV vectors for in vivo gene therapy applications, advancements in vector engineering for improved targeting and efficacy, and expanding clinical pipelines for AAV-based therapeutics.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global Adeno-associated virus vector manufacturing market in 2023 owing to their significant investments in gene therapy research, development, and commercialization, driving the demand for AAV vectors for therapeutic applications. For instance, Catalent announced in December 2023 that it had acquired Delphi Genetics, a company that manufactured AAV plasmid DNA. Additionally, the contract manufacturing organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of AAV vector manufacturing by pharmaceutical and biotechnology companies to leverage specialized expertise, infrastructure, and scalability offered by CMOs.
North American region is anticipated to have the highest revenue share during the forecast period owing to its robust infrastructure for biopharmaceutical manufacturing, a strong regulatory framework supporting gene therapy development, and significant investments in research and development by pharmaceutical companies and academic institutions. Additionally, the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, owing to the increased adoption of gene therapy technologies, increased investment in healthcare infrastructure, and expanding biopharmaceutical industry presence in countries such as China, Japan, and South Korea. For instance, Sarepta Therapeutics reported encouraging first findings from their Phase I/II clinical study of SRP-9001, an AAV-based gene therapy, for Duchenne muscular dystrophy in January 2024.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
AAV-based medicines are becoming more widely available as a result of the pharmaceutical industry's increasing investment in gene therapy research and development. The need for AAV vector manufacturing services is anticipated to rise as more gene therapy candidates go through preclinical and clinical development. For instance, FUJIFILM Diosynth Biotechnologies stated in February 2024 that it has formed a strategic cooperation with a prominent gene therapy company to facilitate the development and production of AAV-based gene therapies.
By therapeutic area, the genetic disorders segment accounted for the highest revenue-grossing segment in the global Adeno-associated virus vector manufacturing market in 2023 owing to the growing demand for gene therapy treatments for a wide range of genetic diseases, coupled with advancements in AAV vector technology enabling safe and effective gene delivery. For instance, Thermo Fisher Scientific announced in March 2024 the release of the new GibcoTM AAVMAXTM Titer Kit for AAV vector manufacturing. Additionally, the oncology segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cancer, expanding research in oncology gene therapy, and the potential of AAV vectors to deliver targeted therapies with fewer side effects.
By application, the gene therapy segment accounted for the highest revenue-grossing segment in the global Adeno-associated virus vector manufacturing market in 2023 owing to the escalating demand for innovative treatments for genetic diseases, coupled with advancements in AAV vector technology facilitating safer and more efficient gene delivery. For instance, Oxford Biomedica stated in December 2023 that it would be expanding its Oxford, UK, manufacturing plant in order to meet the growing demand for the manufacture of AAV vectors. Additionally, the cell therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of cell-based treatments for various diseases, advancements in AAV vector technology for cell transduction, and expanding applications of cell therapies in regenerative medicine and immunotherapy.
By method, the in vitro segment accounted for the highest revenue-grossing segment in the global Adeno-associated virus vector manufacturing market in 2023 owing to the growing demand for AAV vectors in research and development applications, including cell-based assays, gene editing, and drug discovery. For instance, uniQure N.V. reported encouraging interim data from the Phase I/II clinical trial of AMT-130, an AAV-based gene therapy intended to treat Huntington's disease, in January 2024. Additionally, the in vivo segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of AAV vectors for in vivo gene therapy applications, advancements in vector engineering for improved targeting and efficacy, and expanding clinical pipelines for AAV-based therapeutics.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global Adeno-associated virus vector manufacturing market in 2023 owing to their significant investments in gene therapy research, development, and commercialization, driving the demand for AAV vectors for therapeutic applications. For instance, Catalent announced in December 2023 that it had acquired Delphi Genetics, a company that manufactured AAV plasmid DNA. Additionally, the contract manufacturing organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing outsourcing of AAV vector manufacturing by pharmaceutical and biotechnology companies to leverage specialized expertise, infrastructure, and scalability offered by CMOs.
North American region is anticipated to have the highest revenue share during the forecast period owing to its robust infrastructure for biopharmaceutical manufacturing, a strong regulatory framework supporting gene therapy development, and significant investments in research and development by pharmaceutical companies and academic institutions. Additionally, the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, owing to the increased adoption of gene therapy technologies, increased investment in healthcare infrastructure, and expanding biopharmaceutical industry presence in countries such as China, Japan, and South Korea. For instance, Sarepta Therapeutics reported encouraging first findings from their Phase I/II clinical study of SRP-9001, an AAV-based gene therapy, for Duchenne muscular dystrophy in January 2024.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Therapeutic Area, Application, Method, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Adeno Associated Virus Vector Manufacturing Market Report 2023 - 2034
Adeno Associated Virus Vector Manufacturing Market Analysis & Forecast by Therapeutic Area 2023 - 2034 (Revenue USD Bn)
- Hematological Diseases
- Infectious Diseases
- Genetic Disorders
- Neurological Disorders
- Ophthalmic Disorders
- Others
Adeno Associated Virus Vector Manufacturing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cell Therapy
- Gene Therapy
- Vaccine
Adeno Associated Virus Vector Manufacturing Market Analysis & Forecast by Method 2023 - 2034 (Revenue USD Bn)
- In Vitro
- In Vivo
Adeno Associated Virus Vector Manufacturing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutions
- Contract Manufacturing Organizations (CMOs)
- Hospitals and Clinics
Adeno Associated Virus Vector Manufacturing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Adeno Associated Virus Vector Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
8. Adeno Associated Virus Vector Manufacturing Market: Application Estimates & Trend Analysis
9. Adeno Associated Virus Vector Manufacturing Market: Method Estimates & Trend Analysis
10. Adeno Associated Virus Vector Manufacturing Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Adeno Associated Virus Vector Manufacturing Market
13. Europe Global Adeno Associated Virus Vector Manufacturing Market
14. Asia Pacific Global Adeno Associated Virus Vector Manufacturing Market
15. Latin America Global Adeno Associated Virus Vector Manufacturing Market
16. MEA Global Adeno Associated Virus Vector Manufacturing Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Lonza Group
- Thermo Fisher Scientific Inc.
- Oxford Biomedica plc
- FUJIFILM Diosynth Biotechnologies
- uniQure N.V.
- Catalent Inc.
- Brammer Bio (now Thermo Fisher Scientific)
- Regenxbio Inc.
- Cobra Biologics (part of the Cognate BioServices group)
- Vigene Biosciences Inc.
- Sarepta Therapeutics Inc.
- 4D Molecular Therapeutics
- Asklepios BioPharmaceutical (AskBio)
- Spark Therapeutics (acquired by Roche)
- MeiraGTx Holdings plc.
